Method and compositions for treating dystrophies and myotonia

a dystrophic and myotonia technology, applied in the field of methods and compositions for treating myotonia and dystrophies, can solve problems such as no known cur

Active Publication Date: 2019-11-28
NEXIEN BIOPHARMA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0022]The at least one cannabinoid may be synthetic or naturally occurring, and is preferably selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabidivarin (THCV), tetrahydrocannabinolic acid (THCA), cannabidivarin (CBDV), cannadidiolic acid (CBDA), the various isomers and enantiomers thereof, and combinations and mi

Problems solved by technology

There are currently no known cures for muscular dystrophy, however,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and compositions for treating dystrophies and myotonia
  • Method and compositions for treating dystrophies and myotonia
  • Method and compositions for treating dystrophies and myotonia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0216]The following capsules comprising THC (dronabinol), CBD and sesame oil may be prepared as described in U.S. Pat. No. 6,703,418.

CAPSULE ATHCCBD(mg)(mg)12.55022.57532.510042.512552.515062.517572.520082.522592.5250102.5275112.5300122.5325132.5350142.5375152.5400162.5425172.5450

CAPSULE BTHCCBD(mg)(mg)1550257535100451255515065175752008522595250105275115300125325135350145375155400165425175450

CAPSULE CTHCCBD(mg)(mg)17.55027.57537.510047.512557.515067.517577.520087.522597.5250107.5275117.5300127.5325137.5350147.5375157.5400167.5425177.5450

CAPSULE DTHCCBD(mg)(mg)110502107531010041012551015061017571020081022591025010102751110300121032513103501410375151040016104251710450

CAPSULE ETHCCBD(mg)(mg)115502157531510041512551515061517571520081522591525010152751115300121532513153501415375151540016154251715450

[0217]The capsule formulations A1-A17; B1-B17; C1-C17; D1-D17; E1-E17 may be administered to patients diagnosed with type 1 myotonic dystrophy so a target steady state plasma level of about 1 ...

example 2

[0224]The following solutions comprising THC (dronabinol), CBD and liquid carriers such as water, ethanol, polyethylene glycol, propylene glycol and combinations thereof may be prepared as described in U.S. Pat. No. 8,222,292:

SOLUTION ATHCCBD(mg / mL)(mg / mL)10.51020.51530.52040.52550.53060.53570.54080.54590.550

SOLUTION BTHCCBD(mg / mL)(mg / mL)10.751020.751530.752040.752550.753060.753570.754080.754590.7550

SOLUTION CTHCCBD(mg / mL)(mg / mL)111021153120412551306135714081459150

SOLUTION DTHCCBD(mg / mL)(mg / mL)11.51021.51531.52041.52551.53061.53571.54081.54591.550

SOLUTION ETHCCBD(mg / mL)(mg / mL)12.01022.01532.02042.02552.03062.03572.04082.04592.050

SOLUTION FTHCCBD(mg / mL)(mg / mL)12.51022.51532.52042.52552.53062.53572.54082.54592.550

SOLUTION GTHCCBD(mg / mL)(mg / mL)131023153320432553306335734083459350

[0225]The solution formulations A1-A9 to G1-G9 may be administered to patients diagnosed with type 1 myotonic dystrophy so a target steady state plasma level of about 1 to 10 ng / mL of THC is obtained. Preferabl...

example 3

[0235]The present example provide support for one embodiment of the present invention that a potential therapeutic effect of cannabis for the treatment of myalgia and myotonia occurs through the presence of cannabinoid receptors in muscles and by modulation of both central and peripheral pain pathways.

[0236]Herein, the effects of a combination of THC / CBD is demonstrated in six patients with dystrophic and non-dystrophic myotonia in whom other therapies for myotonia / stiffness and myalgia failed to achieve any satisfactory response.

Patients and Methods

[0237]A combination of cannabidiol and tetrahydrocannabinol (CBD / THC) was prescribed as compassionate use to six consecutive patients complaining of myotonia and myalgia who were not satisfactorily responding to standard treatments. Genetically confirmed diagnoses were: myotonic dystrophy type 1 (2 patients), myotonic dystrophy type 2 (2 patients), and congenital myotonia due to mutations in CLCN1 (1 patient with Becker myotonia and 1 pa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

Methods and compositions for treating myotonia and dystrophies.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part application of U.S. application Ser. No. 15 / 899,160, filed on Feb. 19, 2018, which is a non-provisional application, which claims the benefits of U.S. Provisional Patent Application Ser. No. 62 / 460,941 filed on Feb. 20, 2017 and are incorporated herein by reference.TECHNICAL FIELD OF THE INVENTION[0002]The present invention relates to methods and compositions for treating myotonia and dystrophies such as muscular dystrophies. The methods comprise the administration of a composition comprising a cannabinoid and / or a terpene to a patient in need of such treatment.BACKGROUND OF THE INVENTION[0003]Myotonia is a condition present in a number of neuromuscular disorders such as myotonia congenital, paramyotonia congenital and myotonic dystrophy, and is characterized by a delayed relaxation of muscles after voluntary contraction.[0004]Muscular dystrophy is a general term that describes a group of genetic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/353A61K31/05A61K47/44A61P21/00A61K9/00
CPCA61K31/05A61K47/44A61K31/353A61P21/00A61K9/006A61K31/352
Inventor KLUMPERS, LINDASCHOSER, BENEDIKTGOLDFARB, ROBERTFRIEDLAND, JEFFREY
Owner NEXIEN BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap